Public Companies
Field Trip Health & Wellness To Webcast Live at the KCSA Mental Health Conference on December 15th
Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman…
Field Trip Health & Wellness Ltd. (TSXV: FTHW), a global leader in the delivery of psychedelic therapies, today announced that Ronan Levy, Chairman & Chief Executive Officer of Field Trip Health & Wellness, will webcast live at the KCSA Mental Health Conference, hosted by VirtualInvestorConferences.com, on Thursday, December 15th, 2022.
DATE: December 15, 2022
TIME: 11:00 a.m. ET
LINK: https://bit.ly/3Ub0iE3
A recording of the webcast presentation will be available on the Events and Presentations section of Field Trip’s investor relations website following the events.
The Field Trip management team will also participate in one-on-one investor meetings following the conference. For institutional investors to schedule a meeting, please contact fieldtripIR@kcsa.com.
Recent Company Highlights
- Provided a business update and reported fiscal second quarter 2023 results.
- Launched Freedom by Field Trip™, a first-of-its-kind one-year hybrid ketamine therapy program that blends the power of psychedelic-assisted therapies with holistic wellness support.
- Announced the relaunch and refresh of its award-winning psychedelic app, now named Field Trip.
- Strengthened leadership team with two executive appointments.
About Field Trip Health & Wellness Ltd
With a large global community of psychedelic-interested people, proprietary psychedelic therapies that generate transformative results for people in the treatment of mental health conditions and a brand and share of voice that is reaching millions of people, Field Trip is a center of gravity for the psychedelic renaissance.
-
Psychedelics7 days agoCybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin6 days agoAre Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week agoNuminus reports declining revenue as the company restructures
-
Law & Regulation7 days agoGoing concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psychedelics7 days agoOptimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics7 days agoPsyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics6 days agoAtai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation5 days agoClearmind signs agreement with Hebrew University for psychedelic compound rights